Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Here's a roundup of top developments in the biotech space over the last 24 hours:
(Biotech stocks hitting 52-week highs on Nov. 20)
(Biotech Stocks Hitting 52-week lows on Nov. 20)
See Also: Analyst: Peak Sales Potential Of Amarin's Vascepa Underappreciated
Cellectis SA (NASDAQ:CLLS) said the European Patent EP3004337, which was challenged in May 2018, was upheld by the European Patent Office. The patent pertains to a method of preparing T-cells for immunotherapy using the CRISPR-Cas9 system, and was initially granted to the company Aug. 2, 2017.
The stock rose 5.05% to $13.74 in after-hours trading.
Therapix Biosciences Ltd – ADR (NASDAQ:TRPX) has received a written notice of delisting from the Nasdaq, with the company found flouting the listing standards regarding shareholders' equity requirement. Consequently, the company's ADSs will be suspended from trading on the Nasdaq at the opening of trading Nov. 29. Therapix said it intends to appeal the decision.
The stock declined 10.10% to $1.35 in after-hours trading.
Hepion Pharmaceuticals Inc (NASDAQ:HEPA) said its CRV431, an anti-fibrotic agent, prevented the development of liver cirrhosis in highly aggressive preclinical model of liver disease. The results, according to the company, contributed preclinical efficacy data that complements its ongoing human clinical trials.
The stock skyrocketed 60.74% to $3.89 in after-hours trading.
Neon Therapeutics Inc (NASDAQ:NTGN) announced a new strategic focus and a corporate restructuring, as it plans to focus its efforts on the on the advancement of both personal and precision neoantigen-targeted T cell therapy candidates. As part of restructuring, the company plans to reduce its workforce by 24% and cease taking on new additional spending commitments related to its cancer vaccine programs NEO-PV-01 and NEO-SV-01.
The company also said it plans to explore strategic alternatives.
The stock rallied 18.88% to $1.70 in after-hours trading.
Following a Type B pre-IND meeting with the FDA, Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) said it plans to submit an IND application for its TNX-102 SL, a potential treatment for alcohol use disorder. The will support a Phase 2 proof-of-concept study in the first quarter of 2020.
The stock rose 11.64% to $1.63 in after-hours trading.
Bristol-Myers Squibb Co (NYSE:BMY) announced the completion of its proposed $74 billion acquisition of Celgene Corporation (NASDAQ:CELG), about 11 months after the deal was announced. Celgene now becomes a wholly-owned subsidiary of Bristol-Myers.
Bristol-Myers stock added 1.54% to $57.28 in after-hours trading.
Karuna Therapeutics Inc (NASDAQ:KRTX) shares found some strength after hours after Wedbush raised the price target for the shares from $38 to $134. Separately, the company said it has priced its previously announced 2.6 million follow-on offering at $96 per share.
The stock rose 3.95% to $113.25 in after-hours trading.
OptiNose said it and certain selling stockholders intend to offer its common stock in an underwritten public offering. The company said it plans to use the net proceeds for working capital and general corporate purposes.
The stock slipped 6.40% to $10.68 in after-hours trading.
Crispr Therapeutics AG (NASDAQ:CRSP) priced its previously-announced common stock offering at $64.50 per share. The company expects to raise gross proceeds of $274.1 million from the offering. The offering is expected to close on or about Nov. 25.
The stock fell 1.51% to $66.40 in after-hours trading.
Molecular Templates Inc (NASDAQ:MTEM) announced the commencement of an underwritten public offering of its common stock and newly-designated Series A convertible preferred stock. All the shares earmarked for the offering are sold by the company.
The stock moved down 3.26% to $8 in after-hours trading.
Entera Bio Ltd (NASDAQ:ENTX) (before the market open)
Enanta Pharmaceuticals Inc (NASDAQ:ENTA) (after the close)
Posted In: ACOR AEMD AFMD ALNY AMGN ANCN ARAV ARVN ATRS AXSM BBIO BGNE BIO BMY CAPR CELG CKPT CLLS CRSP CUE